Elsevier (company)

Elsevier (company)
Name	Elsevier
Type	Subsidiary
Industry	Publishing
Founded	1880
Founder	Jacobus George Robbers
Headquarters	Amsterdam, Netherlands
Parent	RELX

Elsevier (company) is a global publishing firm specializing in scientific, technical, and medical literature, operating within publishing conglomerates and scientific communication networks. It publishes journals, books, databases, and analytical platforms that serve researchers, universities, hospitals, and corporations across continents in collaboration with academic societies and research institutions. Its operations intersect with debates involving scholarly societies, library consortia, funding agencies, and regulatory bodies.

History

Elsevier traces origins to a 19th‑century imprint linked by name to a historical Dutch family of printers and a 17th‑century publishing tradition associated with the Dutch Golden Age, with corporate foundations emerging in the Netherlands and expansions into London and New York. Over decades, growth involved partnerships with scientific societies such as the Royal Society and academic publishers including Springer and Wiley, and acquisitions under parent conglomerates leading to integration with Reed International and later RELX. Major milestones include launches of journal platforms that intersect with citation indexes like those maintained by Clarivate and database developments paralleling initiatives from the National Institutes of Health and the Wellcome Trust. The firm’s timeline reflects interactions with university presses, research funders, and open access proponents such as the Public Library of Science and Plan S advocates.

Corporate structure and operations

Elsevier operates as a subsidiary within RELX Group and maintains corporate headquarters in Amsterdam with major operational centers in London and New York, coordinating editorial workflows across editorial offices, production facilities, and digital platforms. Its organizational units oversee peer review processes involving editorial boards drawn from universities, collaborations with learned societies like the American Chemical Society and the Institute of Electrical and Electronics Engineers, and partnerships with database providers such as Scopus and ScienceDirect. The company’s supply chain includes relationships with indexing services, library consortia including Jisc and CRKN, and procurement channels linked to university libraries, hospital systems, and corporate research departments.

Products and services

Elsevier’s portfolio includes flagship journal collections, monograph series, and electronic resources delivered via platforms comparable to ScienceDirect, Scopus, and clinical decision tools akin to ClinicalKey, used by clinicians at hospitals and researchers at universities. It offers bibliometric analytics and research management tools that interface with university repositories, grant offices such as those at the National Science Foundation and European Research Council, and manuscript submission systems employed by scholarly societies and academic publishers. The company licenses content to academic libraries, corporate R&D centers, and government laboratories, and provides editorial services, article processing charge frameworks used by open access journals, and educational solutions utilized in medical schools and engineering faculties.

Controversies and criticism

Elsevier has faced criticism from academics, library organizations, and advocacy groups including the Faculty of 1000, the Scholarly Publishing and Academic Resources Coalition, and open access campaigners for pricing models and subscription practices affecting university budgets and research access. Disputes have involved negotiation stalemates with national library consortia such as those in Germany, Sweden, and the Netherlands, and protests from researchers affiliated with institutions like Harvard University, the Max Planck Society, and the University of California. Critics have cited comparisons with other major publishers including Springer Nature, Wiley, and Taylor & Francis, raising concerns about profit margins, embargo policies, and article processing charges tied to hybrid journal models.

Legal actions and policy disputes

Legal and policy disputes involving Elsevier have included litigation and contract negotiations with organizations such as the Association of Research Libraries and national agencies, regulatory scrutiny from antitrust authorities in various jurisdictions, and debates before legislative bodies dealing with open access mandates like those proposed by the European Commission and national research funders. The company has engaged in copyright enforcement actions and takedown notices against repositories including ResearchGate and institutional archives, intersecting with copyright law interpretations involving the Copyright, Designs and Patents Act, the Digital Millennium Copyright Act, and policies set by the US National Institutes of Health. These disputes have involved stakeholders such as scholarly societies, university consortia, technology platforms like Google Scholar, and funders including the Wellcome Trust.

Financial performance and market position

Elsevier occupies a leading market position among STM publishers with revenue streams derived from journal subscriptions, licensing deals, and analytics services, contributing to parent company RELX’s financial results reported to investors and market analysts on exchanges comparable to Euronext and the London Stock Exchange. Its financial performance is benchmarked against peers such as Springer Nature, Wiley, and others, and is influenced by negotiations with library consortia including Big Deal arrangements, shifts toward open access funded by research councils, and competitive pressures from platforms like PubMed Central and emerging scholarly communication startups. Market valuation, profit margins, and strategic investments reflect interactions with investment firms, corporate governance bodies, and international research policy trends.

Category:Publishing companies